Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infe...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-04-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-017-0010-z |
| _version_ | 1827775407525462016 |
|---|---|
| author | Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi |
| author_facet | Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi |
| author_sort | Andrés Sanchez Alberti |
| collection | DOAJ |
| description | Chagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infectious cardiac inflammation and puts one-sixth of the population of Latin America at risk of infection. International collaborators led by Emilio Malchiodi, of the University of Buenos Aires, Argentina, constructed a vaccine (dubbed ‘Traspain’) comprised of key T. cruzi proteins alongside a novel ‘adjuvant’—designed to promote the efficacy of a vaccine by activating inflammatory responses. The chimera and adjuvant combination elicited a promising immune response and also showed the capacity to prevent tissue damage caused by chronic infection. Multi-part vaccines such as Traspain offer an attractive direction for research into vaccines against chronic parasitic infections. |
| first_indexed | 2024-03-11T13:49:27Z |
| format | Article |
| id | doaj.art-ae1f0273188b48babe69f8e20ee1e766 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-11T13:49:27Z |
| publishDate | 2017-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-ae1f0273188b48babe69f8e20ee1e7662023-11-02T09:23:46ZengNature Portfolionpj Vaccines2059-01052017-04-012111210.1038/s41541-017-0010-zEngineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infectionAndrés Sanchez Alberti0Augusto E. Bivona1Natacha Cerny2Kai Schulze3Sebastian Weißmann4Thomas Ebensen5Celina Morales6Angel M. Padilla7Silvia I. Cazorla8Rick L. Tarleton9Carlos A. Guzmán10Emilio L. Malchiodi11Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICETUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICETUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICETDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection ResearchDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection ResearchDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection ResearchUniversidad de Buenos Aires, Facultad de Medicina, Departamento de Patología, Instituto de Fisiopatología CardiovascularCenter for Tropical and Emerging Global DiseasesUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICETCenter for Tropical and Emerging Global DiseasesDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection ResearchUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICETChagas disease: protecting from chronic parasitic disease An amalgamation of parasitic proteins may be the first effective vaccine against the as yet untreatable chronic phase of Chagas disease. The infliction, caused by the parasite Trypanosoma cruzi (T. cruzi), is the world’s leading cause of infectious cardiac inflammation and puts one-sixth of the population of Latin America at risk of infection. International collaborators led by Emilio Malchiodi, of the University of Buenos Aires, Argentina, constructed a vaccine (dubbed ‘Traspain’) comprised of key T. cruzi proteins alongside a novel ‘adjuvant’—designed to promote the efficacy of a vaccine by activating inflammatory responses. The chimera and adjuvant combination elicited a promising immune response and also showed the capacity to prevent tissue damage caused by chronic infection. Multi-part vaccines such as Traspain offer an attractive direction for research into vaccines against chronic parasitic infections.https://doi.org/10.1038/s41541-017-0010-z |
| spellingShingle | Andrés Sanchez Alberti Augusto E. Bivona Natacha Cerny Kai Schulze Sebastian Weißmann Thomas Ebensen Celina Morales Angel M. Padilla Silvia I. Cazorla Rick L. Tarleton Carlos A. Guzmán Emilio L. Malchiodi Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection npj Vaccines |
| title | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection |
| title_full | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection |
| title_fullStr | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection |
| title_full_unstemmed | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection |
| title_short | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection |
| title_sort | engineered trivalent immunogen adjuvanted with a sting agonist confers protection against trypanosoma cruzi infection |
| url | https://doi.org/10.1038/s41541-017-0010-z |
| work_keys_str_mv | AT andressanchezalberti engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT augustoebivona engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT natachacerny engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT kaischulze engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT sebastianweißmann engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT thomasebensen engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT celinamorales engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT angelmpadilla engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT silviaicazorla engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT rickltarleton engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT carlosaguzman engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection AT emiliolmalchiodi engineeredtrivalentimmunogenadjuvantedwithastingagonistconfersprotectionagainsttrypanosomacruziinfection |